CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CD20 CAR-T 疗法抢先治疗 CD19 CAR-T 治疗后部分缓解的复发/难治性弥漫大 B 细胞淋巴瘤患者
英文原题：CD20CAR-T Therapy Preemptively Treats Patients with Relapsed/Refractory DLBCL in Partial Remission after CD19CAR-T.
查看英文原题
CD20CAR-T Therapy Preemptively Treats Patients with Relapsed/Refractory DLBCL in Partial Remission after CD19CAR-T.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
复发/难治性弥漫大B细胞淋巴瘤（r/r DLBCL）患者在接受CD19CAR-T 细胞治疗（CD19CAR-T）后仅达到部分缓解（PR）者面临高进展风险。
本研究评估了CD20CAR-T 治疗作为抢先巩固方案在此类情况下的疗效。我们利用北京高博博仁医院研究登记系统进行了一项回顾性分析，纳入接受针对不同B细胞抗原的序贯CAR-T 细胞治疗的患者。纳入2019年至2022年间接受CD19CAR-T 后达到PR并随后接受CD20CAR-T 的成人r/r DLBCL患者。19例患者符合入组标准。接受CD20CAR-T 后，16例患者（84.2%）达到完全缓解（CR）。中位随访29.4个月（范围，8.8-43.0个月），中位无进展生存期（PFS）为27.0个月（95%置信区间[CI]，14.6至未达到[NR]），中位总生存期（OS）未达到。未观察到重度细胞因子释放综合征（CRS，3级）或重度免疫效应细胞相关神经毒性综合征（ICANS，3级）。这些数据提示，CD20CAR-T 作为抢先巩固治疗在CD19 CAR-T 后处于PR的r/r DLBCL患者中显示出应用前景。
展开英文摘要原文
Patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) who achieve only a partial remission (PR) following CD19 chimeric antigen receptor T-cell therapy (CD19CAR-T) face a high risk of progression.
This study evaluated the efficacy of CD20CAR-T therapy as a preemptive consolidation approach in this setting.
We conducted a retrospective analysis using the Beijing Gobroad Boren Hospital research registry for patients treated with sequential CAR-T cell therapies targeting distinct B-cell antigens. Adult patients with r/r DLBCL who achieved PR after CD19CAR-T and subsequently received CD20CAR-T between 2019 and 2022 were included. Nineteen patients met the eligibility criteria. Following CD20CAR-T, 16 patients (84. 2%) achieved complete remission (CR). With a median follow-up of 29.
4 months (range, 8. 8-43. 0 months), the median progressive-free survival (PFS) was 27. 0 months (95% confidence interval [CI], 14. 6 to not reached [NR]), and the median overall survival (OS) was not reached. No severe cytokine release syndrome (CRS, grade 3) or severe immune effector cell-associated neurotoxicity syndrome (ICANS,grade 3) was observed. These data suggest that CD20CAR-T shows promise as a preemptive consolidation therapy in patients with r/r DLBCL in PR after CD19 CAR-T.
论文信息
- 作者
- Xue F、Shi H、Liu R、Fu Z、Yang F、Deng B、Zheng P、Feng S
- 第一作者单位
- Department of Lymphoma and Myeloma Research Center, Beijing Gobroad Boren Hospital, Beijing, China.China
- 通讯作者单位
- Department of Lymphoma and Myeloma Research Center, Beijing Gobroad Boren Hospital, Beijing, China. Electronic address: huk@gobroadhealthcare.com.China
- 期刊
- Transplantation and cellular therapy2025 Nov
- 原文标识
- PubMed 40749945 · DOI 10.1016/j.jtct.2025.07.018